Replies to post #9988 on Mymetics Corp (MYMX)

[Work Harder]

I'd say that small research project w/ Sanofi

Is a lil more than small

Sanofi has a direct interest in gp41

Mymx will get some revs in time b/c they get a small piece in a license eventually for HIV w/ larger players than Catalent

& most likely across multiple diseases

[Work Harder]

transmembrane gp41 from clade B, and Gag/Pro from clade B and was used previously in the RV144 phase III clinical trial

https://jvi.asm.org/content/89/16/8525

[Work Harder]

Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

https://seekingalpha.com/article/4187810-gileads-hiv-franchise-assault-stares-paradigm-changing-drug

Other drug makers like GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), and Bristol-Myers Squibb (BMY) round out the top 11 drugs for HIV and are looking for cracks in GILD’s HIV franchise to exploit. They are likely meeting with CYDY in anticipation of the approval, and if they get wind of a monotherapy filing, this could spark a fight for control of the next generation of HIV treatment.

[Work Harder]

T20 peptide (enfuvirtide) is the first U.S. FDA-approved HIV entry inhibitor; however, its clinical application is limited by the lack of oral availability

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775441/

Enfuvirtide binds to gp41 preventing the creation of an entry pore for the capsid of the virus, keeping it out of the cell

https://en.wikipedia.org/wiki/Enfuvirtide

[Work Harder]

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Rome, Italy. [e-mail]

https://www.ncbi.nlm.nih.gov/pubmed/16129831

[Work Harder]

Appreciate his efforts but

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144344281